Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 2/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4011481 | 1.00 | S1PR2 (0.44) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL4015251 | 1.00 | S1PR2 (0.44) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL4011475 | 1.00 | S1PR2 (0.44) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL19441221 | 0.92 | S1PR2 (0.40) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL15534599 | 0.92 | S1PR2 (0.40) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL14823590 | 0.89 | S1PR2 (0.52) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL10713383 | 0.88 | S1PR2 (0.46) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL9820755 | 0.87 | S1PR2 (0.38) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL4369973 | 0.87 | S1PR2 (0.38) | S1PR2S1PR4S1PR1S1PR3S1PR5 | |
| SCHEMBL15508649 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | disclosed |
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-11-12 | — | — | US | disclosed |
| US-7576122-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7528163-B2 | N,N-Dibutyl-2-[3-(2,2-dimethylpropanoyl)-6-methoxy-1H-indazol-1-yl]acetamide; potassium channel blocker; eye neuroprotectant; hypotensive agent; glaucoma, intraoccular pressure in the eye | MERCK & CO. INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| EP-1664011-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2008-11-20 | — | — | US | disclosed |
| US-7414067-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414067-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2008-08-19 | — | — | US | disclosed |
| WO-2007108968-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-1581503-A4 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO INC (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-12-07 | — | — | US | disclosed |
| EP-1664011-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20060020000-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME CORP. | 2006-01-26 | — | — | US | disclosed |
| EP-1581503-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005020917-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004043354-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281154-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN1, KCNN3, KCNN2 | S1PR2 907/4885S1PR4 1816/4885S1PR1 1009/4885 |
| US-20060276504-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | S1PR2 885/4885S1PR4 1898/4885S1PR1 759/4885 |
| US-20080287489-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNJ11 | S1PR2 882/4885S1PR4 1921/4885S1PR1 845/4885 |
| US-20060020000-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNH3, KCNJ11 | S1PR2 882/4885S1PR4 1921/4885S1PR1 845/4885 |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | S1PR2 875/4885S1PR4 1742/4885S1PR1 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.